T Helper 2 Inhibitors in Allergic Contact Dermatitis
Autor: | Catherine M. Ludwig, Vivian Y. Shi, Jeffrey M. Krase |
---|---|
Rok vydání: | 2020 |
Předmět: |
business.industry
Dermatology medicine.disease Dupilumab Delayed hypersensitivity response Clinical trial 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine T helper 2 Delayed hypersensitivity Immunology Immunology and Allergy Medicine 030212 general & internal medicine business Allergic contact dermatitis |
Zdroj: | Dermatitis. 32:15-18 |
ISSN: | 2162-5220 1710-3568 |
Popis: | Clinical trials are currently underway to evaluate the benefit of dupilumab in treating allergic contact dermatitis (ACD). Dupilumab use has been reported to improve ACD reactions in some patients, but not all. Varying clinical responses to T helper 2 (TH2) inhibition challenge the classical view that ACD proceeds through a TH1-dominant pathway. Selective TH2 inhibitors, such as dupilumab, may attenuate ACD when the delayed hypersensitivity response is due to TH2-predominate activation; conversely, it may have no effect on ACD if it is elicited via TH1 or TH17 pathways. We hypothesize that allergen-specific T-cell responses and patient-specific factors both play an important role in determining which pathways are recalled in delayed hypersensitivity reactions. |
Databáze: | OpenAIRE |
Externí odkaz: |